Introduction
============

Colorectal cancer is the most common malignant tumor in the digestive tract and has a high incidence ([@b1-ol-0-0-10525]). According to statistics, more than 8 million new colorectal cancer cases were reported worldwide in 2016, and the cumulative number has reached \~300 million ([@b2-ol-0-0-10525]). In colorectal cancer patients, intestinal obstruction is a very common tumor complication, and there are studies indicating that the risk of colorectal cancer patients with intestinal obstruction is as high as 10--30% ([@b3-ol-0-0-10525]). The body of patients with colon cancer is in a very weak state, the occurrence of intestinal obstruction at this time causes acid-base imbalance, water and electrolyte disorders, and intestinal surgery cannot be performed routinely ([@b4-ol-0-0-10525]). Edema and hyperemia are common in the intestinal tract of obstruction segment. Patients with acute tumor condition can only be operated by stages, which not only increases the risk and cost of surgery, but also has a great negative effect on the prognosis of patients ([@b5-ol-0-0-10525]). According to statistics, the effective cure rate of colorectal cancer patients with intestinal obstruction is only 60--80% ([@b6-ol-0-0-10525]) and intestinal obstruction is one of the main reasons for the poor prognosis of colorectal cancer patients. In the face of this situation, continuous research and development of colorectal cancer in clinic can effectively improve the prognosis of patients with intestinal obstruction. With the application of neoadjuvant chemotherapy, the tumor focus is first reduced by chemotherapy, and then resected by surgery, which can significantly improve the curative effect of the patients ([@b7-ol-0-0-10525]). Trans-anal ileus catheter and intestinal metal stent implantation are the latest laparoscopic surgery adjuvant therapy, which can not only effectively improve the tumor resection rate, but also greatly increase the rate of primary intestinal anastomosis and they have been proved to have a very high application value in obstructive colorectal cancer ([@b8-ol-0-0-10525]--[@b10-ol-0-0-10525]). However, the application of trans-anal ileus catheter and intestinal metal stent implantation in obstructive colorectal cancer worldwide is mostly used as guidance study ([@b11-ol-0-0-10525],[@b12-ol-0-0-10525]), and a relatively rare comparison exists of the exact curative effect between them. Since 2016, Taizhou Hospital has popularized the use of trans-anal ileus catheter, intestinal metal stent implantation combined with cancer laparoscopic surgery and neoadjuvant chemotherapy in the treatment of obstructive colorectal cancer patients, and has achieved significant results. There is still controversy on surgical treatment of obstructive colorectal cancer worldwide. To the best of our knowledge, there is no accurate research to propose which method is most suitable for patients with obstructive colorectal cancer. Therefore, this study compared the clinical effects of intestinal stent and trans-anal ileus catheter combined with laparoscopic surgery and neoadjuvant chemotherapy respectively in patients with obstructive colorectal cancer to provide reference and guidance for the selection of surgical schemes for patients with obstructive colorectal cancer.

Patients and methods
====================

### General data

Patients with obstructive colorectal cancer treated in Taizhou Hospital of Zhejiang Province, Wenzhou Medical University (Taizhou, China), from February 2016 to March 2017 were selected for retrospective analysis. Inclusion criteria: Patients in accordance with the clinical manifestations of colorectal cancer and highly suspected as colorectal cancer in Taizhou Hospital of Zhejiang Province, Wenzhou Medical University ([@b13-ol-0-0-10525]), after pathological biopsy, confirmed as colorectal cancer with intestinal obstruction. Patients had trans-anal ileus catheter and intestinal metal stent implantation combined with laparoscopic surgery and neoadjuvant chemotherapy in the hospital after diagnosis. Patients aged 30 to 70 years; patients who were willing to cooperate with the medical staff, and patients with complete records. Exclusion criteria: Patients with other tumors; patients with cardiovascular and cerebrovascular diseases; patients with severe cardiopulmonary dysfunction; pregnant patients; patients with chemotherapy tolerance; patients with physical disabilities; long-term bedridden patients; patients with mental illness; patients transferred to hospital in midway; patients who had received radiotherapy and chemotherapy before admission. In total, 89 cases were selected, including 67 males and 22 females with an age range of 38--67 years and an average age of 51.69±10.77 years. Forty-nine of 89 patients treated with intestinal metal stent implantation combined with laparoscopic surgery and neoadjuvant chemotherapy were the stent group. The other 40 cases treated with trans-anal ileus catheter combined with laparoscopic surgery and neoadjuvant chemotherapy were the catheter group.

This study was approved by the Ethics Committee of Taizhou Hospital of Zhejiang Province, Wenzhou Medical University. Patients who participated in this research, signed an informed consent and had complete clinical data.

Methods
-------

### Study design

Two groups of patients underwent intestinal obstruction surgery followed by tumor resection and chemotherapy after surgery. The clinical efficacy and prognosis of the two groups were compared after all courses of treatment.

### Surgical protocol in the stent group

The patients were placed in a left lateral decubitus position. When the enteroscope entered the body and reached the stenotic part, an expansion catheter was used to send the guide wire into the stenotic part under X-ray monitoring. Appropriate stent was chosen according to the length and width of the tumor invading intestine (NDS-20-080-230; Beijing YuLongKeTai Trading Co., Ltd., Beijing, China). A stent pusher was used to drive the stent along the wire to the stenotic part, both ends exceeding the narrow point at least by 2 cm. The changes of vital signs were closely monitored after stent placement.

### Surgical protocol in the catheter group

Endoscopy entered into the obstruction for angiography after lavage of obstruction of the distal intestinal. If the contrast agent was unable to pass through the narrow area, the catheter placement was abandoned, if it passed, the guide wire was inserted from the biopsy hole, and through the narrow part under X-ray monitoring. A clamp expander was inserted along the guide wire and the enteroscope was pulled out. The intestinal obstruction catheter (D1407-0518; Dalian Create Medic International Trade Co., Ltd.) was inserted into the airbag near the narrow area along the clamp expander, and the guide wire and the clamp expander were pulled out to complete the catheter placement. The vital signs of the patients were closely monitored after catheterization, and warm saline 1000--1500 ml was used daily to wash the obstruction catheter.

### Laparoscopic surgery

All the patients were operated by physicians with secondary senior professional title or above in Oncological Surgery of the hospital. The stents in the stent group were removed with tumor resection during surgery, and the catheters in the catheter group were removed before the surgery.

### Neoadjuvant chemotherapy regimen

MFOLFOX6 protocol was used, including oxaliplatin (EB01714; Shanghai Shifeng Biological Technology Co., Ltd.) 85 mg/m^2^, intravenous drip, d~1~. Calcium folinate (RB768; Shanghai GuangRui Biological Technology Co., Ltd.) 200 mg/m^2^, intravenous drip, d~1~. Fluorouracil for injection (0597-5G; Qingdao Jisskang Biotechnology Co., Ltd.) 400 mg/m^2^, venous injection, d~1~. Then fluorouracil 2.0 g/m^2^ was added to the chemotherapeutic pump for 48 h intravenous drip, repeated every 2 weeks, and the duration of chemotherapy was 2--3 months.

### Observation indicators

Preoperative indicators: Clinical information such as sex, age, tumor stage and differentiation degree of patients in the two groups. Intraoperative indicators: The intestinal preparation time, surgical duration, intraoperative blood loss and open surgery rate (open surgery was performed when the tumor was not completely resected by laparoscopic surgery) of patients in the two groups were observed. Postoperative indicators: postoperative exhaust time and adverse reaction rate (including postoperative anastomotic fistula, incision infection and lower extremity venous thrombosis). Prognostic indicators: All the patients were included in prognostic follow-up of reexamination at 1 year in hospital to record the local recurrence rate and incision tumor implantation rate.

### Statistical analysis

The data were analyzed and processed by SPSS 24.0 statistical software (Beijing Bizinsight Information Technology Co., Ltd.). The enumeration data were expressed in the form of a rate. Chi-square test was used for comparison between the groups. The measured data were expressed as mean ± standard deviation, and t-test was used for comparison between the two groups. P\<0.05 was considered statistically significant.

Results
=======

### Preoperative indicators

There was no significant difference in age, body weight, disease course, the count of platelet, erythrocytes and leukocytes, time interval after stent/tube insertion, sex, smoking, alcohol consumption, exercise habit, ethnicity, pathological stage, lymphatic metastasis, differentiation, intestinal obstruction degree, primary tumor, histological type and lymph node dissection between the two groups (P\>0.05), which proved that the two groups were comparable ([Table I](#tI-ol-0-0-10525){ref-type="table"}).

### Intraoperative indicators

The intestinal preparation time in the stent group (4.16±1.24 days) was shorter than that in the catheter group (7.14±1.78 days) (P\<0.001); The surgical duration in the stent group (127.68±34.74 min) was longer than that in the catheter group (104.67±26.77 min) (P\<0.001). The intraoperative blood loss in the stent group (49.87±13.81 ml) was higher than that in the catheter group (32.73±11.57 ml) (P\<0.001) ([Fig. 1A-C](#f1-ol-0-0-10525){ref-type="fig"}). Two patients underwent open surgery in the stent group, and the open surgery rate was 4.08%; 3 patients underwent open surgery in the catheter group, and the open surgery rate was 7.50%. There was no significant difference in the open surgery rate between the two groups (P\>0.05) ([Table II](#tII-ol-0-0-10525){ref-type="table"}).

### Postoperative indicators

The postoperative exhaust time in the stent group was 2.69±1.53 days, which was not significantly different from that in the catheter group (2.75±1.62 days) (P\>0.05). In the stent group, 6.12% (3 cases) of patients had incision infection; 2.04% (1 case) had anastomotic fistula; 2.04% (1 case) had lower extremity venous thrombosis; 4.08% (2 cases) had abdominal infection; 8.16% (4 cases) had abdominal pain; 6.12% (3 cases) had fever, and the incidence of adverse reactions was 28.57% (14 cases). In the catheter group, 5.00% (2 cases) of patients had incision infection; 5.00% (2 cases) had anastomotic fistula; 5.00% (2 cases) had abdominal infection; 7.50% (3 cases) had abdominal pain; 10.00% (4 cases) had fever, and the incidence of adverse reactions was 32.50% (13 cases). There was no significant difference in the incidence of adverse reactions between the two groups (P\>0.05) ([Fig. 1D](#f1-ol-0-0-10525){ref-type="fig"} and [Table II](#tII-ol-0-0-10525){ref-type="table"}).

### Prognostic indicators

Eighty-six of 89 subjects were followed up successfully, and the success rate was 96.63%. Two participants were lost to follow-up in the stent group and 1 case in the catheter group. There was no incision tumor implantation in either group. In the stent group, 2.13% (1 case) of patients had hepatic metastasis, 2.13% (1 case) had gastric metastasis, and the local recurrence rate was 4.26% (2 cases); In the catheter group, 2.56% (1 case) of patients had pulmonary metastasis, 2.56% (1 1case) had brain metastasis, and the local recurrence rate was 5.13% (2 cases). There was no significant difference in local recurrence rate between the two groups (P\>0.05) ([Table II](#tII-ol-0-0-10525){ref-type="table"}).

Discussion
==========

There is a high probability of intestinal obstruction in patients with colorectal cancer which may lead to the reduction of resection rate, increase of intestinal orifice rate, and a significant increase in risk of death after surgery ([@b14-ol-0-0-10525]). Because of intestinal obstruction, preoperative bowel preparation is not possible for colorectal cancer patients. Patients were usually performed proximal obstruction of intestinal fistula first and then resection surgery, and an intestinal stoma reversion was conducted after the surgery ([@b15-ol-0-0-10525],[@b16-ol-0-0-10525]). Multiple trauma surgery causes more damage to patients who are already suffering from cancer, and the sequelae of trauma surgery multiplies ([@b17-ol-0-0-10525],[@b18-ol-0-0-10525]). With the widespread use of endoscopic stents and trans-anal ileus catheterization in recent years, the clinical efficacy of patients with obstructive colorectal cancer has significantly improved. At present, endoscopic stent and trans-anal ileus catheterization combined with laparoscopic surgery in the treatment of obstructive colorectal cancer has achieved significant research results, which has great value in improving the success rate of the surgery of obstructive colorectal cancer. Through endoscopic stent and trans-anal ileus catheterization, the intestinal obstruction of colorectal cancer patients can be relieved by non-operative method ([@b19-ol-0-0-10525],[@b20-ol-0-0-10525]), which makes the tumor resection surgery standard, and not only greatly increase the success rate of resection surgery, but also effectively improve the prognosis of patients.

The clinical value of endoscopic stent and trans-anal ileus catheterization combined with neoadjuvant chemotherapy in laparoscopic resection of obstructive colorectal cancer was compared in this study, and the results showed that the intestinal preparation time in the stent group was shorter than that in the catheter group, which indicated that endoscopic stent was more effective than trans-anal ileus catheterization in relieving intestinal obstruction. The reason might be that the small diameter of trans-anal ileus catheter, the poor effect of defecation rate, disunited defecation of patients and higher stool hardness in some patients can cause intestinal catheter obstruction, resulting in the intestinal preparation time in the catheter group being longer than the stent group. However, the surgical duration and the intraoperative blood loss in the stent group were higher than those in the catheter group, which suggested that trans-anal ileus catheter had higher surgical safety than endoscopic stent in patients with obstructive colorectal cancer. The reason was that intestinal stents might lead to intestinal perforation and bleeding, and stent displacement might lead to abnormal intestinal metabolism in patients ([@b18-ol-0-0-10525]). During the operation, the doctor not only needs to remove the tumor focus completely, but must also remove the implanted stent, which would take more time and blood loss during the surgery than in the catheter group. Catheterization could indirectly improve intestinal edema and intestinal wall blood flow in patients ([@b21-ol-0-0-10525]). The catheter is removed preoperatively, allowing the doctor to focus on the removal of the tumor during the surgery. Smooth environment of the patient\'s intestine is beneficial to surgery. There was no significant difference in open surgery rate, postoperative adverse reactions, exhaust time and prognosis between the two groups, which indicated that trans-anal ileus catheter and endoscopic stent had high application value in patients with obstructive colorectal cancer. Because of the presence of intestinal obstruction, patients with obstructive colorectal cancer usually need to wash their intestines before and after surgery the intestine is the largest digestive organ in the human body, which contains a large amount of feces and bacteria. Once the bacteria invade the body during surgery, it is easy to cause infection, which directly results in the decrease of the immune function of the patients, causes postoperative complications and affects the prognosis. The intestinal function of patients can be improved effectively with trans-anal ileus catheter and endoscopic stent, and combined with intravenous parenteral nutrition intervention can obtain effective nutritional support after surgery, improve the stability and balance of intestinal tract, reduce the occurrence of postoperative adverse reactions, and greatly improve the prognosis of patients.

The purpose of this study was to compare the clinical efficacy of trans-anal ileus catheter and endoscopic stent in patients with obstructive colorectal cancer, but there were still some shortcomings due to the limited experimental conditions. The number of subjects studied was small and the population was relatively uniform. The materials of intestinal obstruction stents are varied. The stents used in this study were all made of metal materials, which did not exclude the possible differences in the efficacy of other materials (such as stainless steel and nickel-titanium alloy). A longer-term follow-up survey of the subjects in this study will be conducted.

In conclusion, intestinal metal stent implantation can effectively relieve intestinal obstruction, while trans-anal ileus catheter offers higher safety in laparoscopic surgery. Their combination with neoadjuvant chemotherapy and laparoscopic surgery for obstructive colorectal cancer has high value and good clinical effect. The best treatment plan should be selected according to the patient\'s condition.
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![(A) Comparison of the intestinal preparation time between the two groups. The intestinal preparation time in the catheter group was significantly longer than that in the stent group; \*P\<0.001, compared with the intestinal preparation time in the stent group. (B) Comparison of surgical duration between the two groups. The surgical duration in the catheter group was significantly shorter than that in the stent group; \*P\<0.001, compared with the surgical duration in the stent group. (C) Comparison of intraoperative blood loss between the two groups. The intraoperative blood loss in the catheter group was significantly less than that in the stent group; \*P\<0.001, compared with the intraoperative blood loss in the stent group. (D) Comparison of postoperative exhaust time between the two groups. There was no significant difference in postoperative exhaust time between the catheter and and stent groups; P\>0.05.](ol-18-02-1931-g00){#f1-ol-0-0-10525}

###### 

Clinical data comparison \[n (%)\].

  Factors                                           Stent group (n=49)   Catheter group (n=40)   χ^2^ or t-test   P-value
  ------------------------------------------------- -------------------- ----------------------- ---------------- ---------
  Age                                               50.64±11.57          51.04±10.62             0.168            0.867
  Body weight (kg)                                  76.24±8.67           75.14±8.32              0.606            0.546
  BMI (kg/m^2^)                                     26.13±4.38           27.05±5.15              0.911            0.365
  Disease course (weeks)                            3.17±0.54            3.22±0.50               0.449            0.655
  Platelet (×10^9^/l)                               228.21±50.14         220.42±57.21            0.684            0.684
  Erythrocyte (×10^9^/l)                            4.66±0.64            4.72±0.51               0.481            0.632
  Leukocyte (×10^9^/l)                              8.15±1.17            7.96±1.34               0.714            0.477
  Time interval after stent/tube insertion (days)   12.85±2.36           11.92±2.05              1.960            0.053
  Sex                                                                                            0.192            0.661
    Male                                            36 (73.47)           31 (77.50)                               
    Female                                          13 (26.53)           9 (22.50)                                
  Smoking                                                                                        0.103            0.748
    Yes                                             34 (69.39)           29 (72.50)                               
    No                                              15 (30.61)           11 (27.50)                               
  Alcohol consumption                                                                            0.577            0.448
    Yes                                             40 (81.63)           30 (75.00)                               
    No                                              9 (18.37)            10 (25.00)                               
  Exercise habit                                                                                 0.197            0.657
    Yes                                             5 (10.20)            3 (7.50)                                 
    No                                              44 (89.80)           37 (92.50)                               
  Ethnicity                                                                                      0.485            0.486
    Han                                             47 (95.92)           37 (92.50)                               
    Minority                                        2 (4.08)             3 (7.50)                                 
  Pathological stage                                                                             0.320            0.572
    Stage I--II                                     24 (48.98)           22 (55.00)                               
    Stage III--IV                                   25 (51.02)           18 (45.00)                               
  Lymphatic metastasis                                                                           0.529            0.467
    Yes                                             17 (34.69)           11 (27.50)                               
    No                                              32 (65.31)           29 (72.50)                               
  Differentiation degree                                                                         0.231            0.891
    Well-differentiated                             27 (55.10)           20 (50.00)                               
    Moderately differentiated                       12 (24.49)           11 (27.50)                               
    Poorly differentiated                           10 (20.41)           9 (22.50)                                
  Intestinal obstruction degree                                                                  0.047            0.828
    Complete                                        32 (65.31)           27 (67.50)                               
    Incomplete                                      17 (34.69)           13 (32.50)                               
  Primary tumor                                                                                  0.041            0.839
    Colon cancer                                    21 (42.86)           18 (45.00)                               
    Rectal cancer                                   28 (57.14)           22 (55.00)                               
  Histological type                                                                              0.136            0.934
    Adenocarcinoma                                  20 (40.82)           15 (37.50)                               
    Mucinous carcinoma                              19 (38.78)           14 (35.00)                               
    Undifferentiated carcinoma                      10 (20.41)           9 (22.50)                                
  Lymph node dissection                                                                          0.054            0.816
    Total mesangiectomy                             16 (32.65)           14 (35.00)                               
    Local excision                                  33 (67.35)           26 (65.00)                               
  Open surgery rate                                 2 (4.08)             3 (7.50)                0.485            0.486
  Incision infection                                3 (6.12)             2 (5.00)                                 
  Anastomotic fistula                               1 (2.04)             2 (5.00)                                 
  Lower extremity venous thrombosis                 1 (2.04)             0 (0.00)                                 
  Abdominal infection                               2 (4.08)             2 (5.00)                                 
  Abdominal pain                                    4 (8.16)             3 (7.50)                                 
  Fever                                             3 (6.12)               4 (10.00)                              
  Incidence of adverse reactions (%)                28.57                32.50                   0.161            0.688
  Hepatic metastases                                1 (2.04)             0 (0.00)                                 
  Pulmonary metastasis                              0 (0.00)             1 (2.56)                                 
  Brain metastases                                  0 (0.00)             1 (2.56)                                 
  Gastric metastasis                                1 (2.04)             0 (0.00)                                 
  Local recurrence rate (%)                         4.26                 5.13                    0.037            0.848

###### 

Open surgery rate comparison \[n (%)\].

  Factors                              Stent group (n=49)   Catheter group (n=40)   χ^2^ test   P-value
  ------------------------------------ -------------------- ----------------------- ----------- ---------
  Open surgery rate                    2 (4.08)             3 (7.50)                0.485       0.486
  Incision infection                   3 (6.12)             2 (5.00)                            
  Anastomotic fistula                  1 (2.04)             2 (5.00)                            
  Lower extremity venous thrombosis    1 (2.04)             0 (0.00)                            
  Abdominal infection                  2 (4.08)             2 (5.00)                            
  Abdominal pain                       4 (8.16)             3 (7.50)                            
  Fever                                3 (6.12)               4 (10.00)                         
  Incidence of adverse reactions (%)   28.57                32.50                   0.161       0.688
  Hepatic metastases                   1 (2.04)             0 (0.00)                            
  Pulmonary metastasis                 0 (0.00)             1 (2.56)                            
  Brain metastases                     0 (0.00)             1 (2.56)                            
  Gastric metastasis                   1 (2.04)             0 (0.00)                            
  Local recurrence rate (%)            4.26                 5.13                    0.037       0.848
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